The results of a recent multi-center clinical study have shown that oral administration of KOHJIN Glutathione (L-Glutathione Reduced, GSH) is effective against the onset and progress of Non-Alcoholic Fatty Liver Disease (NAFLD), and more broadly, metabolic syndrome. The implications of this study, which was presented at the International Liver Congress 2016 in Barcelona, Spain, are unprecedented as to date no available drug therapy has been shown effective in the treatment of NAFLD, according to the organization.
 
NAFLD, which can progress to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma, is a rising worldwide threat, particularly in the U.S., where the morbidity rate has soared as high as 30%.
 
The study examined 34 subjects who were administered 300 mg daily of glutathione over a period of four months, and concluded with a comparison of both clinical parameters and image-view observation of steatosis (adipose degeneration), with the aid of transient elastography, according to each subject’s detailed profile before and after treatment with glutathione. The improvement in physical condition along both lines was decisive. Alanine aminotransferase (ALT) and Controlled attenuation parameter (CAP/Fibroscan) levels were significantly lowered.
 
Glutathione is a tripeptide prodigiously found in every mammalian cell, the essential function of which is to mediate cellular activity and defy the cellular degradation that takes place when the body fights viral and microbial infection and systemic illness; undergoes stress and exhaustion as a result of everyday life and rigorous physical activity; sustains, through excretion, the onslaught of pollution, toxins and other external factors; and notably, undergoes normal aging, which diminishes the supply of Glutathione in the blood. It acts as an antioxidant, supports liver functioning and purges the system of free radicals.

In 2014 researchers put to rest any remaining uncertainty about whether orally administered glutathione added to the body’s store of the substance, and whether this additional volume of glutathione would work in the same way as that existing naturally.
 
The current study used a reduced form of glutathione with U.S. FDA GRAS, Kosher, and Halal certifications, produced exclusively at the GMP-approved (USP correspondent, non-GMO) manufacturing facilities of KOHJIN Life Sciences. The company plans to conduct large-scale clinical trials going forward.
 
For more information: www.kohjinls.com/en/